methoxamine has been researched along with Fatty Liver in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Hou, MC; Huang, YT; Lee, FY; Lee, SD; Lin, HC; Tsai, TH; Yang, YY | 1 |
Casteleyn, C; D'Hondt, M; De Winter, B; Francque, S; Kwanten, W; Laleman, W; Michielsen, P; Pelckmans, P; Ramon, A; Van Dyck, C; Van Marck, E; Van Marck, V; Van Steenkiste, C; Verbeke, L; Vermeulen, W | 1 |
2 other study(ies) available for methoxamine and Fatty Liver
Article | Year |
---|---|
Kupffer cell depletion attenuates leptin-mediated methoxamine-stimulated portal perfusion pressure and thromboxane A2 release in a rodent model of NASH-cirrhosis.
Topics: Analysis of Variance; Animals; Arachidonic Acid; Benzofurans; Choline; Clodronic Acid; Diet, High-Fat; DNA Primers; Fatty Acids, Unsaturated; Fatty Liver; Gadolinium; Hemodynamics; Hypertension, Portal; Insulin Resistance; Kupffer Cells; Leptin; Methionine; Methoxamine; Microcirculation; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Rats; Receptors, Thromboxane A2, Prostaglandin H2; RNA, Messenger; Sulfonylurea Compounds; Thiobarbituric Acid Reactive Substances; Thromboxane A2 | 2012 |
Increased intrahepatic resistance in severe steatosis: endothelial dysfunction, vasoconstrictor overproduction and altered microvascular architecture.
Topics: Analysis of Variance; Animals; Cytokines; Endothelin-1; Endothelium, Vascular; Fatty Liver; Hypertension, Portal; Liver; Liver Circulation; Liver Cirrhosis; Male; Methoxamine; Microscopy, Electron, Scanning; Microvessels; Nitric Oxide; Nitric Oxide Synthase Type III; Rats; Rats, Wistar; Thromboxane-A Synthase; Vasoconstriction; Vasoconstrictor Agents | 2012 |